Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Net Margin (2016 - 2025)

United Therapeutics (UTHR) has disclosed Net Margin for 17 consecutive years, with 46.1% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 386003.0% to 46.1% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 41.94% through Dec 2025, down 1408.0% year-over-year, with the annual reading at 41.94% for FY2025, 40.0% up from the prior year.
  • Net Margin hit 46.1% in Q4 2025 for United Therapeutics, up from 42.36% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 21710.0% in Q4 2023 to a low of 3813.92% in Q4 2024.
  • Historically, Net Margin has averaged 929.2% across 5 years, with a median of 40.92% in 2024.
  • Biggest five-year swings in Net Margin: soared 2168312bps in 2023 and later plummeted -2552392bps in 2024.
  • Year by year, Net Margin stood at 27.02% in 2021, then decreased by -1bps to 26.88% in 2022, then skyrocketed by 80676bps to 21710.0% in 2023, then tumbled by -118bps to 3813.92% in 2024, then surged by 101bps to 46.1% in 2025.
  • Business Quant data shows Net Margin for UTHR at 46.1% in Q4 2025, 42.36% in Q3 2025, and 38.76% in Q2 2025.